ProxyMiner / Company

BRISTOL MYERS SQUIBB COBMY

Latest proxy: 2026 · view on SEC ↗ · CIK 0000014272

CEO total pay

$21,879,919

Christopher S. Boerner, Ph.D.Board · 2025

Say on pay

Not disclosed

Use Ask for the underlying narrative

CEO pay ratio

Item 402(u)

131 to 1

Median employee: $167,191

Compensation committee

CD&A

Compensation and Management Development Committee

Per the latest proxy

Filings indexed: 2 · 2026 · 2025

Executive pay

What did they pay them?

From the Summary Compensation Table. Pay mix and YoY are computed from these rows.

ExecutiveRoleTotalYoYPay mixSalaryStockCash incentiveOther
Christopher S. Boerner, Ph.D.Board2025 compensation
Chair and Chief Executive Officer
$21,879,919 16%
91% at-risk
$1,586,346$16,061,399$3,754,684$477,490
David V. Elkins2025 compensation
EVP and Chief Financial Officer
$9,177,590 5%
85% at-risk
$1,140,442$5,981,513$1,799,484$256,151
Samit Hirawat, M.D.2025 compensation
Former EVP, Chief Medical Officer, Head of Development
$10,334,233 20%
65% at-risk
$964,904$5,815,320$928,658$2,625,351
Cristian Massacesi, M.D.2025 compensation
EVP, Chief Medical Officer, Head of Development
$10,072,950
96% at-risk
$388,462$7,853,994$660,876$44,618
Adam Lenkowsky2025 compensation
EVP, Chief Commercialization Officer
$9,340,352
85% at-risk
$1,131,731$6,136,800$1,794,732$250,029
Greg Meyers2025 compensation
EVP, Chief Digital and Technology Officer
$7,181,173
82% at-risk
$1,072,692$4,209,168$1,669,036$230,277

Pay mix: base cash incentive equity other

CD&A excerpt

Compensation discussion & analysis

Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.

Business Overview In 2025, Bristol Myers Squibb made meaningful strategic progress and strengthened our growth profile while navigating a dynamic operating environment and furthering scientific innovation. We enhanced and diversified our portfolio and progressed pipeline assets that will be critical to our success as we navigate an upcoming period of transition, including the loss of exclusivity on multiple products. The Company entered into important collaborations and completed key acquisitions to extend our scientific leadership and advance value creation. Our collective efforts across the organization helped build momentum as we create the foundation for long-term, sustainable growth and strive to become one of the fastest growing biopharmaceutical companies into the next decade. Critical to our performance in 2025 was our continued focus on growth, diversification and innovation — enabling us to bring more truly transformational medicines to patients faster. Working together, we furthered our strong financial position and achieved significant regulatory and clinical milestones. Last year, the company received 18 approvals for initial and expanded indications in the United Stat

Read the full CD&A on SEC.gov ↗

Peer comparison

Who they benchmark against

Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.

Governance

Policy guardrails

  • hedging

    prohibited

    Policy Prohibiting Hedging and Pledging

  • pledging

    prohibited

    Policy Prohibiting Hedging and Pledging

  • clawback

    present

    clawback policy

  • compensation consultant

    independent

    Independent Compensation Consultant

  • compensation committee

    Compensation and Management Development Committee

    Compensation and Management Development Committee Report

Performance markers

Metric facts

  • revenue

    $10.0 billion

    to $22.6 billion in the prior year, representing an increase of 17% on both a reported basis and excluding foreign exchange.compared to $25.7 billion in the prior year, decreasing 15%, or 16% excluding foreign exchange.G

  • operating income

    $16

    Officer’s target bonus amount and the Company Performance Factor. Company performance results for the year led to a Company Performance Factor of 157.66% for 2025. The calculation was based on the following performance a

  • annual incentive payout

    10%

    For the 2025 annual bonus plan, for our employees at the level of SVP+, including our Named Executive Officers, 10% of the company performance factor was based on an SSI Scorecard metric.

  • ceo pay ratio

    131 to 1

    in the 2025 Summary Compensation Table, as $167,191. Dr. Boerner had an annual total compensation equal to the amount included in the “Total Compensation” column of the 2025 Summary Compensation Table, which results in a

  • median employee compensation

    $167,191

    Pay Ratio To determine the ratio of the CEO’s annual total compensation to the median annual total compensation of all employees excluding the CEO, we identified the median employee as of October 1, 2023 using target tot

Ask

Anything about BRISTOL MYERS SQUIBB CO’s 2026 proxy

Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.

Loading the Ask interface…